Emrush Rexhaj, Sarah Bär, Rodrigo Soria, Yasushi Ueki, Jonas D Häner, Tatsuhiko Otsuka, Raminta Kavaliauskaite, George Cm Siontis, Stefan Stortecky, Hiroki Shibutani, David Spirk, Thomas Engstrøm, Irene Lang, Laura Morf, Maria Ambühl, Stephan Windecker, Sylvain Losdat, Konstantinos C Koskinas, Lorenz Räber
BACKGROUND AND AIMS: The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardial infarction (AMI) are unknown. Therefore, we aimed to investigate the effects of the PCSK9 inhibitor alirocumab added to high-intensity statin on FMD, and its association with coronary atherosclerosis in non-infarct related arteries using intracoronary intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS), and optical coherence tomography (OCT)...
March 6, 2024: Atherosclerosis